Literature DB >> 3795020

Pharmacokinetics of dopamine-2 agonists in rats and dogs.

J E Swagzdis, R W Wittendorf, R M DeMarinis, B A Mico.   

Abstract

The absorption, protein binding, blood-to-plasma ratio, renal excretion, and pharmacokinetics of the dopamine-2 agonists (D2-agonists) 4-(2-di-n-propylaminoethyl)-7-hydroxy-2-(3H)-indolone (1), N-(2'-hydroxy-5'-[N,N-di-n-propylaminoethylphenyl])methanesulfonamide (2), and 4-(2-di-n-propylaminoethyl)-2-(3H)-indolone (3) were examined in dogs and rats. On the basis of relative cumulative urinary recoveries of radiolabeled drug, all three compounds are well absorbed in rats and dogs. In dogs, the free fractions in plasma of unchanged 1, 2, and 3, determined by in vitro studies, were 74, 86, and 63%, respectively, and the protein binding was constant with increasing concentration. The blood-to-plasma partition ratios of the respective compounds were 1.22, 1.14, and 1.16 in dogs, and the ratios were constant with increasing concentration. Large differences between species (dogs, rats, and humans) in protein binding and blood-to-plasma ratios were not seen. The clearances (blood or plasma) of 1 and 2 in dogs were significantly greater than the clearance of 3. The clearance of 3 was almost exclusively nonrenal, whereas 13% of 1 and 2 were recovered unchanged in urine. The steady-state volumes of distribution and the distribution and elimination half-lives of the three compounds were not significantly different. Importantly, the mean residence time of 3 (147 min) in dogs was significantly longer than those of 1 (90 min) and 2 (96 min). The results of analogous studies in rats indicate that 1 and 2 are more rapidly metabolized than 3.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3795020     DOI: 10.1002/jps.2600751002

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes.

Authors:  József Simkó; Norbert Szentandrássy; Gábor Harmati; László Bárándi; Balázs Horváth; János Magyar; Tamás Bányász; István Lorincz; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-29       Impact factor: 3.000

2.  Pharmacokinetic screening of o-naphthoquinone 5-lipoxygenase inhibitors.

Authors:  A Rakhit; S K Kuwahara; D R Jones; V F Soliman; A N Kotake; T D Oglesby; J W Wasley; S L Tripp; F L Douglas
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of ropinirole.

Authors:  C M Kaye; B Nicholls
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

4.  Ropinirole in restless legs syndrome and periodic limb movement disorder.

Authors:  Daniel Erichsen; Raffaelle Ferri; David Gozal
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

5.  Inhibition of Na+,K(+)-ATPase in rat renal proximal tubules by dopamine involved DA-1 receptor activation.

Authors:  C Chen; M F Lokhandwala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

Review 6.  The role of DA1- and DA2-receptors in the control of blood pressure.

Authors:  J P Hieble; R J Eden; C de Mey
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

7.  Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model.

Authors:  Olha Shuklinova; Przemysław Dorożyński; Piotr Kulinowski; Sebastian Polak
Journal:  Pharmaceutics       Date:  2022-07-21       Impact factor: 6.525

8.  Update on ropinirole in the treatment of Parkinson's disease.

Authors:  Holly A Shill; Mark Stacy
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.